Trouble reading this e-mail? View it in your browser.

EFPIA
Newsletter
26 January 2017
Header
Header image
News

News

European Commission Initiative Improves Information for Patients on Biosimilar Medicines
23 January 2017

The European Commission Q&A on biosimilar medicines provides a unique resource for patients to enhance understanding and trust in medicines across Europe. The document was written [...] Read more

From our blog

From our blog

Ageing Nation’s Heritage to Benefit Registry-Based Research (Guest blog)
25 January 2017 by

Five million Finns represent one of the most rapidly ageing populations in Europe. An ageing population translates into increasing future healthcare expenses.

The focus of public health problems is moving from cardiovascular diseases and mental health problems to cancers and neurological diseases. We know that the change is ongoing, but new information on its impact is still needed.

Read more

Events calendar

Events Calendar

DIA BioVenture Day
On 28/03/2017 (Glasgow, UK)

DIA is excited to convene its 1st BioVenture Day, in a unique format with the participation of a very broad set of senior healthcare stakeholders. You will be able to explore whether the current BioVenture paradigm is delivering returns for patients, investors, and the healthcare system.

Read more

Events Calendar

DIA EuroMeeting 2017
From 29/03/2017 to 31/03/2017 (Glasgow, UK)

The DIA EuroMeeting 2017 is unique in presenting the entire healthcare microcosm, ranging from policy and regulations, to R&D marketing and access.

In an intense and stimulating three days, you will enjoy learning and debating. You will meet not only people you know, but also those that you want to know and those that you should know.

The DIA EuroMeeting allows you to debate the issues across the entire drug development value chain during the conference, and find solutions within the exhibition with 2,500+ other cross-functional thought leaders.

You will hear the latest solutions and challenges in healthcare. You will have plenty of opportunities to network and build relationships with trend-setters in e.g. the areas of regulatory science, clinical research and operations, value demonstration leads and patient advocates. The resulting knowledge transfer and lasting partnerships will reduce the burden of regulatory barriers, benefiting your business now and further down the line.

Read more

What we are reading

What we are reading

It’s time to reduce, replace and re-think the use of antimicrobials in animals
25 January 2017 (EMA)

EMA - EFSA joint opinion on EU measures to reduce antimicrobials use in animals

Reducing the use of antimicrobials in food-producing animals, replacing them where possible and re-thinking the livestock production system is essential for the future of animal and public health. Antimicrobial resistance (AMR) is one of the world’s most pressing public health issues and the use of antimicrobials in animals contributes to this problem, so limiting their use to the minimum necessary to treat infectious diseases in animals is crucial.

Read more

What we are reading

HARMONY: Better care of patients with haematologic malignancies kicked off!
25 January 2017 (HARMONY)

Attended by 150 participants from 18 countries the HARMONY project successfully kicked off with a two-day meeting on January 16 and 17.

HARMONY is a European Network of Excellence that captures, integrates, analyses and seeks to harmonise Big Data on various haematological malignancies. The Big Data platform that will be developed is foreseen to enable the rapid definition of promising treatment strategies for individual patients.

Read more

What we are reading

‘There will be lots of benefits to patients’ – an interview with the SAFE-T project coordinators
25 January 2017 (IMI)

SAFE-T was among the first IMI projects that started in 2009. Seven years later, the project came to a close, having achieved most of its objectives, and made significant progress in developing improved tools for the prediction, detection, and monitoring of drug-induced injuries to the kidney, liver, and vascular system. In an interview with the IMI Project Office, project coordinator Michael Merz of Novartis, and scientific coordinator Thomas Joos of the Natural and Medical Institute at the University of Tübingen (NMI), share their thoughts on the project’s successes.

Read more

What we are reading

PROactive draws to a close, delivers on its promises – an interview with project coordinators
25 January 2017 (IMI)

PROactive was launched in 2009, with the aim of developing an innovative tool to measure physical activity in chronic obstructive pulmonary disease (COPD) patients. The project has now drawn to a close, meeting its main goal. In an interview with the IMI Programme Office, PROactive’s scientific coordinator, Thierry Troosters of the University of Leuven, and project coordinator, Mario Scuri of CHIESI Pharmaceuticals, explain how the new tool works and how it will benefit patients.

Read more

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
E-mail: communications@efpia.eu
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail